More than 18 months after the Federal Trade Commission (FTC) first launched its inquiry into the effect common business tactics used by pharmacy benefit managers have on consumer drug costs, Senate Commerce Committee Chair Maria Cantwell (D-WA) and Sen. Chuck Grassley (R-ID), joined by 12 other lawmakers, are pressing the commission to provide an update on the study’s progress and soon bring its investigation to a close. While the senators say they respect the process needed to carry out FTC’s...